Evidence map›Paper›PMID 32582155›Full record

ArticleFrontiers in immunology2020

Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.

Delphine C Malherbe, Constantinos Kurt Wibmer, Molati Nonyane, Jason Reed, D Noah Sather, David A Spencer, Jason T Schuman, Biwei Guo, Shilpi Pandey, Harlan Robins and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Delphine C MalherbeOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Constantinos Kurt WibmerCentre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Molati NonyaneCentre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Jason ReedVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.
D Noah SatherCenter for Global Infectious Disease Center, Seattle Children's Hospital Research Foundation, Seattle, WA, United States.
David A SpencerOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Jason T SchumanBruker Daltonics, Portland, OR, United States.
Biwei GuoOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Shilpi PandeyOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Harlan RobinsFred Hutchinson Cancer Research Center, Seattle, WA, United States.
Byung ParkBiostatistics Unit, Primate Genetic Program Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Deborah H FullerAIDS Division, Department of Microbiology, Washington National Primate Research Center, University of Washington, Seattle, WA, United States.
Jonah B SachaVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.
Penny L MooreCentre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Ann J HessellOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Nancy L HaigwoodOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Oregon National Primate Research Center · USOregon Health & Science University · USNational Health Laboratory Service · ZABruker (United States) · USCentre for the AIDS Programme of Research in South Africa · ZAFred Hutch Cancer Center · USInfectious Disease Research Institute · USUniversity of Washington · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Vaccination design based on natural env genes to elicit broad neutralizing AbsP01AI078064 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HAIGWOOD, NANCY L · 2009 to 2014
$12.1M
Viral Testing CoreU42OD010426 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Andrew Haertel, Lauren Drew Martin · 2013 to 2026
$6.0M
NIAID NIH HHS P01 AI078064NIH HHS P51 OD011092NIH HHS U42 OD010426
6 · The paper itself

Abstract

We report here on HIV-1 immunization results in rabbits and macaques co-immunized with clade C gp160 DNA and gp140 trimeric envelope vaccines, a strategy similar to a recent clinical trial that showed improved speed and magnitude of humoral responses. Clade C envelopes were isolated from CAP257, an individual who developed a unique temporal pattern of neutralization breadth development, comprising three separate "Waves" targeting distinct Env epitopes and different HIV clades. We used phylogeny and neutralization criteria to down-select envelope vaccine candidates, and confirmed antigenicity of our antigens by interaction with well-characterized broadly neutralizing monoclonal antibodies. Using these envelopes, we performed rabbit studies that screened for immunogenicity of CAP257 Envs from timepoints preceding peak neutralization breadth in each Wave. Selected CAP257 envelopes from Waves 1 and 2, during the first 2 years of infection that were highly immunogenic in rabbits were then tested in macaques. We found that in rabbits and macaques, co-immunization of DNA, and protein envelope-based vaccines induced maximum binding and neutralizing antibody titers with three immunizations. No further benefit was obtained with additional immunizations. The vaccine strategies recapitulated the Wave-specific epitope targeting observed in the CAP257 participant, and elicited Tier 1A, 1B, and Tier 2 heterologous neutralization. CAP257 envelope immunogens also induced the development of ADCC and T

Indexed as

ImmunizationImmunogenicity, VaccineAIDS VaccinesAnimalsBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesFemaleHIV-1HIV AntibodiesHIV Envelope Protein gp160HIV InfectionsImmunity, HumoralMacaca mulattaMaleRabbitsAIDS VaccinesBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesgp140 envelope protein, Human immunodeficiency virus 1gp160 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp160Vaccines, DNAADCCco-immunizationenvelope immunogenHIV vaccineneutralizing antibodiesNHPrabbitTFH responses

Identifiers

PMID32582155
PMCPMC7280454
OpenAlexW3032981172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.